Form 4: Ligand Pharmaceuticals CEO Todd Davis Acquires 2,500 Shares
SEC Form 4
Ligand Pharmaceuticals CEO Todd C. Davis purchased 2,500 shares of common stock at a price of $97.3922 per share on August 8, 2024.
Summary
- On August 8, 2024, Todd C. Davis, the CEO of Ligand Pharmaceuticals Inc., acquired 2,500 shares of common stock.
- The purchase price was $97.3922 per share.
- Following the transaction, Davis directly owns 123,010 shares of Ligand Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase could indicate confidence, but it's a relatively small transaction.
Positives
- The CEO's purchase of shares may signal confidence in the company's future performance.
Industry Context
Insider transactions are routinely monitored to gauge executive sentiment regarding their company's prospects. Purchases are often interpreted as a bullish signal.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of transaction: Todd C. Davis purchased 2,500 shares of Ligand Pharmaceuticals Inc. |
| 08/09/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.